Condition: Thymic Tumors · Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
This description comes directly from the study's public registry record.
Yongsheng Wang, Ph.D · 18980602258 · Wangys75@gmail.com
Always discuss trial participation with your own doctor first.
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05683886